Member access

4-Traders Homepage  >  Shares  >  Euronext Paris  >  PCAS    PCA   FR0000053514

PCAS (PCA)

73
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

PCAS : 2011 RESULTS

02/22/2012 | 11:40am US/Eastern

PCAS - 2011 RESULTS

Longjumeau, february 22, 2012

20102011
In millions of euros
Net sales158,5  164,5  
including Pharmaceutical Synthesis99,4  102,1  
Including Fine Speciality Chemicals59,1  62,4  
EBITDA (*)16,1  16,5  
EBITDA margin10,2%10,0%
Current Operating Income (*)3,4  5,4  
Other Operating income and expense-2,2  -1,7  
Financial Result-4,2  -3,6  
Taxes (**)-0,9  -3,1  
Share of profit/loss of associates-0,1  0,2  
Net Result-4,0  -2,8  
Net Result (exluding depreciation of deferred tax asset)-4,0  0,2  
Equity71,6  69,2  
Net debt47,5  53,6  
Gearing0,66  0,77  
Net asset per share5,2  5,1  
(*) of which research tax credit (CIR): 2.8 million euros in 2011 and 2.7 in 2010
(**) including a depreciation of deferred tax asset for an amount of 3 M€ in 2011
Audit procedures have been performed and auditor's report is in progress of being issued.

PCAS Group consolidated turnover was up 3.8% in 2011 compared with 2010.

Pharmaceutical Synthesis
Business was affected during the first five months of the year by the lower planned contribution from the new contract between PCAS and Sanofi, in force as of May 31, 2010. apart from this contract, Exclusive and Generics  Pharma business rose 13.1% in 2011.
Fine Speciality Chemicals
Fine Speciality Chemicals reported growth of 5.6% in 2011.

Current Operating Income rose 60% to 5.4 million euros in 2011, compared with 3.4 million euros in 2010.

Net profit in 2011 was affected by a non recurring depreciation of deferred tax assets of 3 million euros (without any effect on cash), due to the effects of the French Goverment amending tax law for 2011 relating to the conditions for future use of loss carry forwards.

Excluding this non recurring item, net profit for 2011 stood at 0.2 million euros compared with (-4) million euros in 2010.

Net debt was 53.6 million euros as of December 31, 2011, compared with 47.5 million euros as of December 31, 2010, resulting from the increase in the working capital , due in particular to strong growth in turnover in the fourth quarter of 2011, as well as research tax credits, which are only refundable after a 3 years period.

To successfully implement the Group's development strategy, which is based on increasing the share of proprietary products and expanding differentiating technologies, the Board of Directors has asked the Group General Management to focus its action in 2012 on improving profitability and level of working capital.

Next meeting: 2012 Shareholder's Meeting at 9 .a.m. on April 24, 2012, in Longjumeau

About PCAS
PCAS is a fine and speciality chemicals Group that shares an ambition of excellence with its clients.  This client base comprises mainly international groups which are leaders in their markets.  PCAS designs and delivers the best industrial solutions to the specific expectations of its clients.  These wide-ranging expectations share in common a demand for safety, quality, competitiveness, innovation and sustainability.

PCAS_2011earning:
http://hugin.info/143512/R/1588264/498366.pdf



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: PCAS via Thomson Reuters ONE

HUG#1588264
React to this article
Latest news on PCAS
03/27 PCAS : Confirmation of PEA-PME plan eligibility for 2015/2016
03/18 PCAS : MOONLINER® by ENERSENS: ultra-insulating natural-based wall cladding
02/19 PCAS : 2014 Results - Strong Financials and growth prospects lead to return to d..
01/29 PCAS : Expansia has been nominated by UCB Pharma "Vendor of the year 2014"
2014 PCAS : ENERSENS Homeskin project
2014 PCAS : leads the European Union Horizon 2020 Homeskin
2014 PCAS : includes a new Scientific Board in its governance
2014 PCAS : Protéus : At the heart of the Vadébio project
2014 PCAS : joins the new EnterNext© PEA-PME 150 index
2014 PCAS : through its subsidiary Proteus, is contributing to the conversion of wood..
Advertisement
Chart
Duration : Period :
PCAS Technical Analysis Chart | PCA | FR0000053514 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF